Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 105 |
| PDBID: | 1N8Z |
| Chains: | BA_C |
| Organism: | Mus musculus, Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 2.52 |
| Reference: | 10.1038/nature01392 |
| Antibody | |
| Antibody: | Herceptin Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Anbenitamab(Phase-II/III); Anvatabart(Phase-II/III); Cinrebafusp(Phase-II); Coprelotamab(Phase-III); Fidasimtamab(Phase-I); Runimotamab(Phase-I); Timigutuzumab(Phase-I); Trastuzumab(Approved); Zanidatamab(Preregistration); |
| Antigen | |
| Antigen: | Receptor protein-tyrosine kinase erbB-2 |
| Antigen mutation: | No |
| Durg Target: | P04626 |
Sequence information
Antibody
Heavy Chain: B
Mutation: NULL
| >1N8Z_B|Chain B|Herceptin Fab (antibody) - heavy chain|Mus musculus (10090) EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP |
Light Chain: A
Mutation: NULL
| >1N8Z_A|Chain A|Herceptin Fab (antibody) - light chain|Mus musculus (10090) DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: C
Mutation: NULL
| >1N8Z_C|Chain C|Receptor protein-tyrosine kinase erbB-2|Homo sapiens (9606) TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPIN |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: ASP28 ASN30 THR31 ALA32 TYR49 SER50 PHE53 ARG66 HIS91 TYR92 THR93 THR94 B: TYR33 ARG50 TYR52 TYR57 ARG59 TRP99 GLY101 ASP102 GLY103 PHE104 TYR105 C: PRO557 GLU558 ASP560 GLN561 LYS569 ASP570 PRO571 PRO572 PHE573 VAL575 PRO579 ILE591 LYS593 ASP596 GLU598 ALA600 CYS601 GLN602 PRO603 CYS604 PRO605 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
